PostDay One-Step (levonorgestrel) NDC 69953-618

NDC codes

FDA NDC Directory

Product NDC (as listed)69953-618Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69953-0618Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69953-618-43	69953061843	1 BLISTER PACK in 1 CARTON (69953-618-43) / 1 mg in 1 BLISTER PACKMarketed from Nov 21, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): PostDay One-Step
Generic name (nonproprietary): levonorgestrel
Active ingredients: Levonorgestrel — 1.5 mg/1.5mg
Dosage form: Tablet
Route: Oral
Labeler: Rapha Pharmaceuticals, Inc.
Product type: Over-the-counter drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205329
Marketing start: Nov 21, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Inhibit Ovum Fertilization (Physiologic effect)Progesterone Congeners (Chemical structure)Progesterone Congeners (Chemical structure)
Identifiers: Product ID 69953-618_0aab0d9b-3db7-7c71-e063-6394a90a9c89SPL ID 0aab0d9b-3db7-7c71-e063-6394a90a9c89SPL set ID 6f7f5697-acb6-ea95-e053-2991aa0ae7c7RxCUI 483325, 2049247UNII 5W7SIA7YZW
Pharmacologic class: Progestin; Progestin-containing Intrauterine System

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469953061843 followed by a unit qualifier and the quantity

Package 69953-0618-43. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 21, 2023.

Indications (excerpt from the label)

USE for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205329

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205329
Product	Strength	Form · route	Labeler	Product NDC
Morning Afterlevonorgestrel	Levonorgestrel 1.5 mg/1.5mg	TabletOral	Rapha Pharmaceuticals, Inc.	69953-516
Morning Afterlevonorgestrel	Levonorgestrel 1.5 mg/1.5mg	TabletOral	Rapha Pharmaceuticals, Inc.	69953-517
PostDay One-Steplevonorgestrel	Levonorgestrel 1.5 mg/1.5mg	TabletOral	Rapha Pharmaceuticals, Inc.	69953-617
PostDay One-Steplevonorgestrel	Levonorgestrel 1.5 mg/1.5mg	TabletOral	Rapha Pharmaceuticals, Inc.	69953-628
Levonorgestrel	Levonorgestrel 1.5 mg/1	TabletOral	Xiromed LLC	70700-164